Fig. 2: The immunological landscape of LUAD is influenced by oncogenic driver alterations.

A Prevalence of 17 cell types, across 157 patients with LUAD as a proportion of total cells. B Prevalence of lymphoid and myeloid cells as a proportion of total cells across 6 oncogenic driver patient groups: Unknown driver (n = 40), KRAS (n = 71), EGFR (n = 26), MET (n = 9), PIK3CA (n = 8), BRAF (n = 3). Comparisons within individual oncogenic driver groups were performed using two-sided Wilcoxon tests, comparisons between oncogenic drivers were performed using two-sided Mann-Whitney tests. C Prevalence of indicated cell types as a proportion of total cells across 6 oncogenic driver patient groups, Unknown driver (n = 40), KRAS (n = 71), EGFR (n = 26), MET (n = 9), PIK3CA (n = 8), BRAF (n = 3). Two-sided Mann-Whitney tests were used for statistical analysis. D Pie chart depicting the proportion of unclassified cells that are CD45+ across 157 LUAD patients. E Prevalence of lymphoid, myeloid, cancer and endothelial cells as a proportion of total cells across 6 oncogenic driver patient groups stratified by sex: Unknown driver male (n = 23), Unknown driver female (n = 17), KRAS male (n = 20), KRAS female (n = 51), EGFR male (n = 8), EGFR female (n = 18), MET male (n = 7), MET female (n = 2), PIK3CA male (n = 4), PIK3CA female (n = 4), BRAF male (n = 2), BRAF female (n = 1). Comparisons between sex within individual oncogenic driver groups and between driver groups by sex were performed using a 2-way ANOVA. F Prevalence of indicated cell types as a proportion of total cells across 4 patient groups with different EGFR point mutations, p.E746_A750del (n = 7), p.G719A (n = 4), p.L858R (n = 9), Other (n = 6). Two-sided Mann-Whitney tests were used for statistical analysis. Source data are provided as a source data file.